VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Personalized risk-profiling for acute leukemia patients undergoing haploidentical allo-HCT

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, outlines a study investigating a novel approach to personalized risk-profiling for acute leukemia patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation (allo-HCT). The study analyzed data from 2001 patients in the European Society for Blood and Marrow Transplantation registry who underwent haploidentical allo-HCT for acute leukemia, and models were developed to explore leukemia-free survival outcomes in these patients. The approach will allow the use of risk-guided interventions in patients with leukemia. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter